PrJSC Lekhim-Kharkiv, a member of the Lekhim Pharmaceutical Group (Kyiv), increased its net profit by 6.9 times in January-June 2024 compared to the same period in 2023, to UAH 29.894 million.
As the company reported in the information disclosure system of the National Securities and Stock Market Commission (NSSMC), net sales revenue in January-June 2024 increased by 46.5% to UAH 369.934 million.
As reported, in 2023, Lekhim-Kharkiv PrJSC reduced its net profit by 6.9 times to UAH 15.169 million, while net sales revenue in 2023 decreased by 10.6% to UAH 560.38 million. At the same time, the company’s sales in 2023 amounted to UAH 430.124 million in the domestic market (88.29% of total sales), sales in non-CIS countries amounted to UAH 38.464 million (7.90% of total sales), and in the neighboring countries the company sold products worth UAH 18.6 million (3.82% of total sales).
Lekhim JSC owns 100% of Lekhim-Obukhiv LLC, 98.2% of Lekhim-Kharkiv PrJSC, 81% of Technolog (Cherkasy region), 100% of Lekhim-Vilnius CJSC and 100% of Lekhim’s foreign representative office in Uzbekistan.
